Results of a preliminary study using hypofractionated involved-fi eld radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer
Introduction
At present, the standard evidence-based treatment for advanced non-small-cell lung cancer (NSCLC), based on data in patients with locally advanced disease, is considered to be concurrent chemotherapy (CHT)-radiation therapy (RT) with a platinum-based regimen. 1 This concurrent CHT-RT provides a median survival time (MST) of 16-17 months, a 1-year overall survival (OAS) rate of 60%-70%, and a 2-year OAS rate of 30%-40%, [2] [3] [4] [5] but these results should be open to further improvement. In addition, there is a problem regarding the fact that grade 3/4 radiation esophagitis occurs in 20%-30% of these patients. [3] [4] [5] Local recurrence is one reason for the poor survival rate after RT, and it has been reported that an improvement in local control leads to increased survival in locally advanced NSCLC. 6, 7 Therefore, intensifi cation of the in-fi eld effect to improve local control has previously been attempted. However, even though an increase in the total dose and a shortening of the overall treatment time are effective for Abstract Background. We aimed to evaluate the feasibility and efficacy of hypofractionated involved-fi eld radiation therapy (IFRT) omitting elective nodal irradiation (ENI) with concurrent chemotherapy for locally advanced non-small-cell lung cancer (NSCLC). Methods. Between July 2004 and July 2006, ten patients with locally advanced NSCLC were included in this study. One had stage IIIA and 9 had stage IIIB disease. The treatment consisted of IFRT in fractions of 2.5 Gy and weekly carboplatin (CBDCA)/paclitaxel (PTX). Hypofractionated IFRT with a median total dose of 65 Gy with median percent total lung volume exceeding 20 Gy (V20) of 20.2%, and a median of fi ve courses of chemotherapy with weekly CBDCA (area under the curve, 1.5-2.0)/PTX (30-35 mg/ m 2 ) were given to all patients.
improving the local control, problems remain due to the increase in severe esophagitis and pneumonitis. Recently, involved-fi eld radiation therapy (IFRT) omitting elective nodal irradiation (ENI) to achieve improved local control by high total dose irradiation, without increasing toxicity, has been attempted for locally advanced NSCLC, and the results of these attempts suggested that it might be possible to irradiate safely with a high total dose using IFRT. 8, 9 After the publication of these results, we introduced IFRT for locally advanced NSCLC within affi liated institutions of Hiroshima University, in 2001. In addition, we started a preliminary study in 2004 to evaluate the feasibility and effi cacy of hypofractionated IFRT with concurrent carboplatin CBDCA)/paclitaxel (PTX). The once-daily fraction is 2.5 Gy, in order to improve the in-fi eld control due to the high total dose irradiation with a higher fraction dose and to also to shorten the overall treatment time.
Patients and methods
Between July 2004 and July 2006, a total of ten patients with locally advanced NSCLC were enrolled in this preliminary study and were evaluated. Before inclusion, all patients signed a written study-specifi c informed consent. In addition to giving them the details of this study, we also explained that the treatment would be cancelled if they rejected the designed treatment of this study during the treatment period. Eligibility criteria included patients with locally advanced stage IIIA-N2 disease or stage IIIB disease (excluding malignant pleural effusion, malignant pericardial effusion, and lymphangitic carcinomatosis), histologically or cytologically confi rmed NSCLC, age between 20 and 74 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, no prior therapy for this malignancy, and adequate laboratory and pulmonary functions. Adequate laboratory function included a leukocyte count of 4000/mm 3 or more, platelet count of 100 000/ mm 3 or more, hemoglobin 9.5 g/dl or more, total bilirubin level less than or equal to the upper limit of normal, and creatinine clearance of 60 ml/min or more. Adequate pulmonary function was defi ned as a forced expiratory volume in 1 s of more than 1.0 l and PaO 2 of 70 torr or more. Any patients with previous malignancies or severe complications (such as obvious interstitial pneumonitis, advanced pulmonary emphysema, and poorly controlled diabetes) were excluded. Before therapy, all patients were evaluated clinically with a history, physical examination, laboratory examination, radiographic studies, pulmonary function test, and electrocardiogram (ECG). The laboratory examination included a complete blood cell count, liver function studies, renal function studies, and measurement of electrolytes. The radiographic studies included chest X-ray, thoracicabdominal computed tomography (CT), head magnetic resonance imaging (MRI), and bone scintigraphy. Wholebody fl uorodeoxyglucose-positron emission tomography (FDG-PET) scan was not routinely performed.
The patient and tumor characteristics are shown in Table  1 . The patients' median age was 68 years (range, 54-74 years); nine were males, and one was female. Five (50.0%) presented with squamous cell carcinoma, four (40.0%) with adenocarcinoma, and one (10.0%) with large-cell carcinoma. One (10.0%) had stage IIIA disease (T2N2; n = 1) and nine (90.0%) had stage IIIB (T1N3, n = 1; T2N3, n = 5; T4N0, n = 1; T4N1, n = 1; T4N2, n = 1). Regarding the staging, all patients underwent thoracic-abdominal CT, head MRI, and bone scintigraphy. Whole-body FDG-PET/ CT was performed in four patients (40.0%).
All patients were treated with three-dimensional conformal radiation therapy (3DCRT) that was planned with a three-dimensional radiation treatment planning system. All patients underwent treatment-planning CT of the chest for identifi cation of the target and normal anatomy. The treatment-planning CT was performed with continuous slices measuring 5 mm in thickness and with a long scan time of 3 s or more per image without breath-holding, throughout the whole lung and tumor. Only lymph nodes with a short-axis diameter of 10 mm or more on CT were included in the gross tumor volume (GTV-LN) without histological confi rmation, in addition to the primary tumor (GTV-P). However, when lymph node involvement was suspected on FDG-PET/CT according to diagnosis by a PET specialist, lymph nodes with a short axis of less than 10 mm were included in the GTV-LN. In addition, the clinical target volume (CTV) was defi ned as the GTV-P plus the GTV-LN. The planning target volume (PTV) was con- toured around the CTV with a three-dimensional margin of 10-15 mm (thus making allowances for the location of the primary tumor, the respiratory mobility of the tumor, and the setup margin). In addition, a port margin of 5 mm was set around the PTV. The difference between the ENI and IFRT fi elds is shown in Fig. 1 . The doses were calculated at the isocenter with heterogeneity correction algorithms, using both a superposition method (6 patients) and a convolution method (4 patients). The hypofractionated IFRT was delivered on a linear accelerator, using a 6-to 10-MV photon beam. The hypofractionated IFRT was delivered via a coplanar technique or a noncoplanar technique with multiple fi elds to deliver a dose of 2.5 Gy once daily in fi ve fractions weekly, and all radiation fi elds were treated every day. In the course of IFRT, fi eld reductions according to the tumor volume reduction were permitted. The fraction dose setting in this study was selected based on the preliminary results reported by Kimura et al., 10 which included accelerated hyperfractionated IFRT (66-75 Gy in 1.5-Gy twice-daily fractions) +/− concurrent CHT. Before the induction of IFRT, irradiation by using accelerated hyperfractionation was considered for IFRT to shorten the overall treatment time. However, we thought that twicedaily fractions might not be practical under clinical conditions, and we decided to use once-daily fractions of 2.5 Gy, whose biologically effective doses (BED) Gy 10 and BED Gy 3 in a day were almost equivalent to that of twice-daily fractions of 1.5 Gy. It was prescribed that the dose variation within the PTV be limited to between 90% and 107% of the prescribed dose. The maximum dose to the spinal cord was kept at less than 40 Gy. The percent total lung volume (the volumes of both lungs minus the CTV) exceeding 20 Gy (V20) was kept to less than 30% in principle, as a higher volume was a predictive factor for the risk of radiation pneumonitis. 11, 12 The limitation of the V20 value was considered based on the fi ndings of the Radiation Therapy Oncology Group (RTOG) 9311 phase I study performed by Bradley et al., 13 in which the estimated rate of grade 3 or more lung toxicity was 0% after IFRT of 70.9 Gy was given in 2.15-Gy once-daily fractions to patients with V20 values of 25% to less than 37%.
The minimal planned total dose was prescribed to be 60 Gy/24 fractions (BED Gy10 is equivalent to that of 62 Gy/31 fractions). The maximum planned total dose was prescribed according to the V20 value as follows: (1) V20 less than 15%, 70 Gy/28 fractions (BED Gy10 is almost equivalent to that of 74 Gy/37 fractions), (2) 15% ≤ V20 < 25%, 67.5 Gy/26 fractions (BED Gy10 is almost equivalent to that of 70 Gy/35 fractions), (3) 25% ≤ V20 < 30%, 65 Gy/26 fractions (BED Gy10 is almost equivalent to that of 68 Gy/34 fractions). The decision regarding the fi nal total dose was made by the radiation oncologist under these dose settings. The details of IFRT given are shown in Table 2 .
As the concurrent CHT, weekly intravenous CBDCA (area under the curve [AUC], 1.5-2.0) and PTX (30-35 mg/ m 2 ) during IFRT was set up in principle. This regimen and the dose setting were considered based on the fi ndings of a phase I study performed by Ohashi et al., 14 which defi ned the dose level of CBDCA (AUC, 2.0) and PTX (35 mg/m 2 ) in combination with hyperfractionated RT (69.6 Gy in 1.2-Gy twice-daily fractions) with ENI as the maximum tolerated dose. Details of the CHT given are shown in Table 2 .
The tumor response rate was analyzed according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines as follows: complete response (CR), the disappearance of all target lesions; partial response (PR), at least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline longest diameter sum; progressive disease (PD), at least a 20% increase in the sum of the longest diameters of target lesions, taking as a b Fig. 1a,b . Digitally reconstructed radiographs (DRRs) demonstrating a the typical elective nodal irradiation (ENI) fi eld and b the involved-fi eld radiation therapy (IFRT) for a patient with stage IIIA non-small-cell lung cancer (NSCLC). The primary tumor is displayed in red; metastatic lymph nodes are displayed in green; the esophagus is displayed in orange.
On DRR of IFRT, the esophagus is outside the radiation fi eld a reference the smallest sum of the longest diameters recorded since the treatment started or the appearance of one or more new lesions; stable disease (SD), neither sufficient shrinkage to qualify for PR nor suffi cient increase to qualify for PD, taking as a reference the smallest sum of the longest diameters since the treatment started. In-fi eld and out-of-fi eld recurrences were assessed using varying combinations of radiological assessment. In-fi eld recurrence was defi ned as an increase in radiologic abnormality within the irradiated volume that was not considered to be radiation-induced scarring or radiation pneumonitis. Elective nodal failure (ENF) was defi ned as recurrence in any lymph node region that was initially uninvolved, in the absence of in-fi eld recurrence.
Acute and late toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0). Acute toxicity was defi ned as that occurring within 90 days of treatment initiation, while late toxicity was defi ned as that occurring beyond 90 days after treatment initiation. During CHT-RT, CHT and RT were to be interrupted for either grade 3 or greater leukopenia or neutropenia or thrombopenia, and thereafter be resumed when that toxicity had decreased to grade 2 or less. In addition, RT was to be interrupted for grade 3 or greater esophagitis or pneumonitis, and thereafter be resumed when that toxicity had decreased to grade 2 or less.. In addition, the treatment was to be canceled if grade 4 or greater severe toxicity occurred.
The follow-up evaluations were performed at 2-month intervals for the fi rst year, at 3-month intervals for the second year, and at 6-month intervals thereafter. The follow-up evaluation routinely included physical examination, chest X-ray, toxicity assessment, and blood tests. Thoracic-abdominal CT scans were performed at 1, 3, 6, 9, 12, 18, and 24 months after the treatment and when indicated thereafter. A restaging with head MRI and bone scintigraphy was performed at 6-month intervals after the fi rst half year. The actuarial curves of OAS and the in-fi eld tumor control rates were calculated using the Kaplan-Meier method, with the day of treatment as the starting point.
Results
Tumor response, overall survival, and in-fi eld tumor control Of the ten patients, one achieved a CR (10.0%), and nine achieved a PR (90.0%) with a tumor response rate of 100%. The fi nal analysis was performed 17 months after the registration of the last patient. At a median follow up of 18.2 months (range, 9.6-41.9 months), fi ve patients (50.0%) had died at the time of the last follow up. The MST was 29.5 months, and the 1-, 2-, and 3-year OAS rates were 90.0%, 58.3%, and 43.8%, respectively (Fig. 2) . A median time to in-fi eld tumor progression of 18.1 months was obtained, and the 1-, 2-, and 3-year in-fi eld tumor control rates were 60.0%, 45.0%, and 45.0%, respectively (Fig. 3) .
Toxicity
The acute treatment-related toxicities are shown in Table  3 . No hematological toxicities of grade 3 or worse were observed. No acute nonhematological toxicities of grade 3 or worse, including radiation esophagitis and radiation pneumonitis, were observed. With a median follow-up time of 36 months for the fi ve surviving patients, only grade 1 pneumonitis/pulmonary infi ltrates, in three patients, and grade 1 fi brosis of the subcutaneous tissue, in one patient, were observed as late toxicities. No late grade 2 or worse toxicities were observed. Therefore, no overall toxicity of grade 3 or worse was observed. The relationships regarding toxicity, tumor factors, and IFRT factors according to total dose are summarized in Table 4 . There was no difference in the CTV value between the patients who were irradiated with a total dose of less than 67.5 Gy and those who were irradiated with a total dose of 67.5-70 Gy. However, the percentage of those with grade 2 esophagitis was higher in the group with less than 67.5 Gy in comparison to the group with a total dose of 67.5-70 Gy.
Patterns of failure
The patterns of failure are shown in Table 5 . Of the ten patients, three (30.0%) were disease-free at the last follow up, and disease recurrences manifested in seven patients (70.0%). In-fi eld recurrences occurred in fi ve patients (50.0%), and out-of-fi eld recurrences were seen in seven patients (70.0%). No ENF was observed. However, regional out-of-fi eld recurrence was observed in one patient who had an in-fi eld recurrence and lung metastasis, this patient had a supraclavicular recurrence in a T2N3 (the primary tumor was located in the left upper lobe). The relationships of the patterns of failure, prognosis, tumor factors, and IFRT factors according to total dose are summarized in Table 6 . No in-fi eld recurrences occurred in the four patients who were irradiated with a total dose of 67.5-70 Gy, and three had no evidence of disease (NED). On the other hand, in-fi eld recurrences occurred in fi ve (83.3%) of the six patients who were irradiated with a total dose of less than 67.5 Gy; no patients had NED, and fi ve died of the disease.
Treatment delivery
Nine of the ten patients (90%) received a higher dose than the minimum planned total dose of 60 Gy that was prescribed in the protocol. One patient (patient 3), who received less than 60 Gy of IFRT had T2N3 disease with multiple contralateral mediastinal nodes. In the course of therapy, this patient had grade 2 esophagitis, and volunteered to stop the treatment when the total dose reached 55 Gy. In three Tables 1  and 2 ) IFRT was completed with a smaller dose than the maximum planned dose, according to the judgment of the radiation oncologist. Incidentally, patients 4 and 8 had N3 disease that had a wide regional spread in the mediastinum, and patient 9 had T4N1 disease whose primary tumor, which had a wide spread, lay adjacent to the esophagus. In these three patients, grade 2 esophagitis developed during the treatment period. Therefore, the radiation oncologist worried that the esophagitis would worsen, and these patients completed treatment with a lower dose than the maximum planned dose.
Discussion
The treatment results of conventional RT for NSCLC have not been satisfactory; therefore, many therapeutic strategies to improve the treatment results have been attempted so far. In stage I NSCLC, stereotactic body radiotherapy (SBRT) has been performed recently, and excellent local control rates, of more than 90%, and OAS of 70%-80%, which matched the results from surgical resection, were reported. [15] [16] [17] We anticipate that SBRT is going to be recognized as a choice for the alternative treatment of stage I NSCLC. In contrast, in locally advanced NSCLC, the standard treatment in the past 20 years has changed dramatically, providing better results. The current standard treatment for locally advanced NSCLC is recognized to be concurrent CHT-RT, but the results provided by concurrent CHT-RT are not entirely satisfactory. Moreover, the optimal details for RT, such as CTV delineation and the irradiated fi eld remain unclear. For many years, it has been thought that standard RT typically entails delivering 40 Gy of ENI to the ipsilateral hilum, the whole mediastinum, and occasionally the supraclavicular fossa even without evidence of disease in these areas, followed by a 20-Gy boost to the GTV. 18 However, it is never easy to irradiate with a high total dose using this irradiation technique with ENI, because the incidence of severe radiation esophagitis and pneumonitis increases with increases in the total dose and ENI has not been shown to be effective.
Recently, IFRT in which ENI is omitted to achieve an improvement in the local control by high-dose irradiation without increasing the toxicity, has been attempted for locally advanced NSCLC. [8] [9] [10] 13, [19] [20] [21] [22] [23] [24] As a result, the possibility of prolongation of the MST and reduction in severe toxicity has been reported, and a low incidence of ENF after IFRT has also been shown. Table 7 lists the results of IFRT trials for NSCLC. At present, 74 Gy in 2-Gy fractions is considered to be the recommended dose setting for IFRT with concurrent weekly CBDCA/PTX for locally advanced NSCLC, according to the results of several phase I and II studies, and it was reported that this treatment provided MSTs of 22-37 months. [22] [23] [24] [25] Furthermore, the RTOG 0617 trial, a randomized phase III study, comparing standard dose (60 Gy) versus high-dose (74 Gy) 3DCRT or intensitymodulated radiation therapy (IMRT) without ENI with concurrent and consolidation CBDCA/PTX for locally advanced NSCLC. is currently underway. Accordingly, many radiation oncologists are interested in the effi cacy of IFRT with concurrent CBDCA/PTX. However, in Japan, no clinical trial of this treatment has yet been performed. Therefore, we consider that a feasibility study of IFRT with concurrent CBDCA/PTX is worth performing in Japan.
In the present preliminary study, the MST and the 1-, 2-, and 3-year OAS in ten patients who were treated with hypofractionated IFRT in once-daily fractions of 2.5 Gy with concurrent weekly CBDCA/PTX were 29.5 months, 90.0%, 58.3%, and 43.8%, respectively. In addition, no ENF and no grade 3 or worse radiation esophagitis was observed. Moreover, no grade 3 or worse radiation pneumonitis was observed, although the primary site in 70% of the patients was located in the upper lobe, whose risk of pneumonitis is lower than that of the lower lobe. Considering these results, hypofractionated IFRT in once-daily fractions of 2.5 Gy with concurrent weekly CBDCA/PTX is therefore considered to be a feasible and safe irradiation method to increase the total dose without increasing the occurrence of either severe radiation esophagitis or pneumonitis, while also demonstrating a low rate of ENF. In addition, hypofractionated IFRT with a high total dose of 67.5 Gy or more may be a promising modality for improving in-fi eld tumor control and prolonging the OAS. However, we think that a small CTV in the mediastinum may be one of the conditions that will allow us to irradiate patients safely at a high dose. Though the irradiated fi eld is certainly small in IFRT in comparison to the general RT fi eld with ENI, the irradiated volume of the esophagus is never small in patients with N2-3 disease that has a wide and long spread of lymph node metastasis in the mediastinum. In these patients, due to the large irradiated volume of the esophagus, V20 increases. Therefore, in the present study we determined the total irradiated dose according to the V20 value; it seems that patients with a narrow spread of mediastinal lymph node Table 7 . Summary of involved-fi eld radiation therapy for non-small-cell lung cancer Author/Trial metastases could therefore receive a high total dose. As a result, good in-fi eld control and a low rate of esophagitis were achieved in the patients who received a total dose of 67.5-70 Gy.
In the RTOG 0117 phase I study, three of the initial eight patients treated with 75.25 Gy in 2.15-Gy daily fractions with weekly CBDCA/PTX developed dose-limiting pulmonary toxicity. Therefore, it was concluded that the toxicity of the high total dose with the high fractional dose and concurrent CHT exceeded the safety limit. The phase II portion of RTOG 0117 is now underway to accrue patients at the de-escalated dose level of 74 Gy in 2-Gy daily fractions. Nevertheless, we consider that 75.25 Gy in 2.15-Gy fractions may still be a safe dose fractionation with concurrent CHT, if the total lung V20 values are set at less than 25%, instead of 30% or less, in regard to the eligibility criteria of patients to undergo the RTOG 0117 trial. In the near future we are planning to design a dose-escalation study of hypofractionated IFRT, given in 2.5-Gy fractions with concurrent weekly CBDCA/PTX, for patients with total lung V20 values of less than 25%.
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